Jennifer Spear Smith, Wyeth
Jennifer Spear Smith may be soft-spoken and petite, but she is loud, clear, and stands tall for one part of industry that she is clearly passionate about: continuing medical education (CME).
JENNIFER SPEAR SMITH
Executive Director, Medical Education, Wyeth
(JOHN HALPERN)
Jennifer Spear Smith may be soft-spoken and petite, but she is loud, clear, and stands tall for one part of industry that she is clearly passionate about: continuing medical education (CME).
Prior to her current position as executive director of medical education for Wyeth, Spear Smith was a CME provider and before that a professor in physiology at Indiana University and Purdue University's combined medical school program. "Medical school was just a starting point for me," says Spear Smith. "Things change so differently in medicine. There is a system, but it needs improvement so that physicians can be helping patients. That is the reason I go to work every day, to improve patient care."
Spear Smith was attracted to the pharma industry for the ample resources available to guide CME in a direction where she could "make a difference in patient care." And she already has by helping to make Wyeth one of the first pharmaceutical companies to require CME providers, after they conducted a CME activity, to measure its success.
"In 10 years, I hope I am still involved in managing education of physicians where it's my goal to continue in a position that ultimately helps patient care," Spear Smith says. "A pharma company is in the perfect position to make a change with how they conduct business and really gear it toward patient care. When we can do that we will have really revolutionized the business."
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
